Effects of Resveratrol Supplementation on Nonalcoholic Fatty Liver Disease Management An Updated Systematic Review and Meta-analysis

In this study, we aimed to systematically review the studies that investigated the effect of resveratrol in nonalcoholic fatty liver disease (NAFLD). A systematic search of different databases was conducted until June 2021 and a meta-analysis was completed.Six trials involving 232 participants were included. The meta-analysis results showed that serum triglycerides (P = .04), interleukin-6 (P = .01), tumor necrosis factor-alpha (P = .02), and systolic blood pressure (P = .04) levels were decreased significantly in the resveratrol group compared with the placebo group, while other parameters were not changed significantly. Although resveratrol might attenuate NAFLD development, more high-quality trials are required in this field.